Literature DB >> 2154427

Efficacy of azithromycin in the treatment of guinea pigs infected with Legionella pneumophila by aerosol.

R B Fitzgeorge1, A S Featherstone, A Baskerville.   

Abstract

Azithromycin and erythromycin were compared for efficacy in guinea pigs infected with an aerosol containing Legionella pneumophila. When administered intraperitoneally, azithromycin was very effective in the treatment of experimental Legionnaires' disease. Even at the low dose of 3.6 mg/kg/day it gave 100% survival and eliminated lung infectivity two days following infection. In contrast, erythromycin at a much higher dose (96 mg/kg/day) gave only 83.3% survival and failed to eliminate organisms from the lung six days after infection. The histological findings confirmed the superiority of azithromycin. A single dose of azithromycin given intraperitoneally at 3.6 or 14.4 mg/kg gave survival rates of 83.3 and 100%, respectively. Azithromycin was also found to be superior to erythromycin in eliminating lung infectivity and reducing mortality, when administered orally. However, oral administration of azithromycin was not as effective as intraperitoneal when assessed by lung histopathology, although it was still superior to oral erythromycin treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154427     DOI: 10.1093/jac/25.suppl_a.101

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  21 in total

1.  Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species.

Authors:  D M Johnson; M E Erwin; M S Barrett; B B Gooding; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

Review 2.  The activity of azithromycin in animal models of infection.

Authors:  J C Pechère
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

3.  More macrolides.

Authors:  M J Wood
Journal:  BMJ       Date:  1991-09-14

Review 4.  The pharmacokinetics of azithromycin and their clinical significance.

Authors:  H Lode
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 5.  Spectrum of activity of azithromycin.

Authors:  J D Williams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

6.  Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia.

Authors:  G Kinasewitz; R G Wood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

7.  Ribosomal Mutations Conferring Macrolide Resistance in Legionella pneumophila.

Authors:  Ghislaine Descours; Christophe Ginevra; Nathalie Jacotin; Françoise Forey; Joëlle Chastang; Elisabeth Kay; Jerome Etienne; Gérard Lina; Patricia Doublet; Sophie Jarraud
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  In vitro activity of azithromycin against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

9.  In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

10.  Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages.

Authors:  D A Stamler; M A Edelstein; P H Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.